TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06926868: IZABRIGHT-Breast01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable,

Sponsor: Bristol-Myers Squibb · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 600 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$676,368

Rescue Site Savings

+$450,912

Unlock Full NCT06926868 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06926868 Rescue Dossier →